Understanding Ovarian Hyperstimulation Syndrome

Ovarian hyperstimulation syndrome (OHSS) is a potential complication that can occur during infertility treatment. This condition is believed to be caused by the presence of multiple luteinized cysts in the ovaries, which can lead to high levels of hormones and vasoactive substances. As a result, the permeability of the membranes increases, leading to fluid loss from the intravascular compartment.

OHSS is more commonly seen following gonadotropin or hCG treatment, and it is rare with Clomiphene therapy. Approximately one-third of women undergoing in vitro fertilization (IVF) may experience a mild form of OHSS. The Royal College of Obstetricians and Gynaecologists (RCOG) has classified OHSS into four categories: mild, moderate, severe, and critical.

Symptoms of OHSS can range from abdominal pain and bloating to more severe symptoms such as thromboembolism and acute respiratory distress syndrome. It is important to monitor patients closely during infertility treatment to detect any signs of OHSS and manage the condition appropriately. By understanding OHSS and its potential risks, healthcare providers can work to minimize the occurrence of this complication and ensure the safety of their patients.

Possible Diagnoses for Abdominal Pain in Women of Childbearing Age

One of the most likely diagnoses for a woman of childbearing age presenting with abdominal pain is a ruptured ectopic pregnancy. This is especially true if the patient has a history of using an intrauterine device (IUD), has missed a period, and experiences scanty bleeding. However, other possible differential diagnoses include appendicitis, ovarian cysts, and pelvic inflammatory disease.

Appendicitis may cause right iliac fossa pain, but the other symptoms and history suggest an ectopic pregnancy as a more likely cause. A femoral hernia is inconsistent with the clinical findings. Ovarian cysts may also cause right iliac fossa pain, but the other features from the history point to an ectopic pregnancy as a more likely cause. Pelvic inflammatory disease is not consistent with the history described, as there is no offensive discharge and no sexual history provided. Additionally, pelvic inflammatory disease does not cause a delay in the menstrual period.

It is important to always test for pregnancy in any woman of childbearing age presenting with abdominal pain, regardless of contraception use or perceived likelihood of pregnancy. Early diagnosis and treatment of a ruptured ectopic pregnancy can be life-saving.

Management of Premenstrual Syndrome (PMS)

Premenstrual Syndrome (PMS) is a diagnosis of exclusion, characterized by cyclical psychological, behavioral, and physical symptoms during the luteal phase of the menstrual cycle. The exact causes are not yet identified, but studies suggest that the effects of hormones on serotonin and GABA signaling may have a significant role, in addition to psychological and environmental factors.

For moderate PMS, the National Institute for Health and Care Excellence (NICE) recommends the use of new-generation combined oral contraceptives, which prevent the natural cyclical change in hormones seen in the physiological menstrual cycle. Continuous use, rather than cyclical, showed better improvement. Response is unpredictable, and NICE suggests a trial of three months, and then to review.

Referral to a specialist clinic is reserved for women who have severe PMS, resistant to medication, that cannot be managed in the community. Fluoxetine, a selective serotonin reuptake inhibitor, has been used successfully in the treatment of women with severe PMS symptoms or in women with moderate PMS that fails to respond to other treatments.

Lifestyle modification advice is given to patients with mild PMS, including regular exercise, restriction in alcohol intake, smoking cessation, regular meals, regular sleep, and stress reduction. St John’s wort, an over-the-counter herbal remedy, has shown improvement of symptoms in some studies, but its safety profile is unknown, and it can interact with prescribed medication. Its use is at the discretion of the individual, but the patient needs to be warned of the potential risks.

Management Options for Premenstrual Syndrome (PMS)

Treatment Options for Primary Dysmenorrhoea: A Guide for Healthcare Professionals

Primary dysmenorrhoea is a common condition that affects many women of reproductive age. When treating this condition, healthcare professionals have several options to consider. Here, we will discuss the most common treatments and their appropriateness for different patients.

Paracetamol is a suitable first-line treatment for patients with primary dysmenorrhoea who cannot take NSAIDs. If the patient does not wish to conceive, a hormonal contraceptive may also be considered as a first-line treatment.

Gabapentin is not recommended for the treatment of dysmenorrhoea, as it is primarily used for epilepsy and neuropathic pain.

Mefenamic acid and naproxen are both NSAIDs and are recommended as first-line treatments for primary dysmenorrhoea. However, they are contraindicated in patients with a history of asthma triggered by NSAID use.

Oral morphine is not typically used as a first-line treatment for dysmenorrhoea. If NSAIDs and paracetamol are not effective, transelectrical nerve stimulation (TENS) may be trialled. If none of these treatments are effective within 3-6 months, the patient should be referred to a gynaecologist for further assessment.

In summary, healthcare professionals should consider the patient’s medical history and preferences when selecting a treatment for primary dysmenorrhoea. Paracetamol and hormonal contraceptives are suitable first-line treatments, while NSAIDs and TENS may also be effective in some patients. Referral to a specialist may be necessary if initial treatments are not effective.

Postcoital Bleeding

Postcoital bleeding is a condition that occurs when there is trauma to superficial lesions within the vaginal tract. This can be caused by a variety of factors, including cervical trauma, cervical polyps, endometrial and cervical carcinoma, cervicitis, and vaginitis. In some cases, invasive cervical carcinoma may be found in those who are referred to the hospital, accounting for 3.8% of cases.

Vaginitis is also a possibility, but it is more common in elderly patients with low estrogen levels. On the other hand, salpingo-oophoritis, which is usually caused by pelvic inflammatory disease from sexually transmitted infections, typically presents with deep dyspareunia and purulent vaginal discharge. However, post-coital bleeding is highly unlikely to be caused by salpingo-oophoritis.

When dealing with patients who have urinary incontinence, it is important to rule out the possibility of a urinary tract infection or diabetes mellitus. This is particularly relevant for a 64-year-old woman who is experiencing this issue. While stress incontinence may be the cause, a urinalysis should be conducted to ensure that there are no underlying medical conditions that could be contributing to or exacerbating her symptoms. In cases where voiding dysfunction or overflow incontinence is suspected, a post-void residual volume test may be necessary. However, this is more commonly seen in elderly men who may have prostate issues. Cystoscopy is not typically used as a first-line investigation for women with urinary incontinence, but may be considered if bladder lesions are suspected. Urinary flow rate assessment is more commonly used in elderly men or those with neurological symptoms.

Understanding Urinary Incontinence: Causes, Classification, and Management

Urinary incontinence (UI) is a common condition that affects around 4-5% of the population, with elderly females being more susceptible. Several risk factors contribute to UI, including advancing age, previous pregnancy and childbirth, high body mass index, hysterectomy, and family history. UI can be classified into different types, such as overactive bladder (OAB)/urge incontinence, stress incontinence, mixed incontinence, overflow incontinence, and functional incontinence.

Initial investigation of UI involves completing bladder diaries for at least three days, vaginal examination, urine dipstick and culture, and urodynamic studies. Management of UI depends on the predominant type of incontinence. For urge incontinence, bladder retraining and bladder stabilizing drugs such as antimuscarinics are recommended. For stress incontinence, pelvic floor muscle training and surgical procedures such as retropubic mid-urethral tape procedures may be offered. Duloxetine, a combined noradrenaline and serotonin reuptake inhibitor, may also be used as an alternative to surgery.

In summary, understanding the causes, classification, and management of UI is crucial in providing appropriate care for patients. Early diagnosis and intervention can significantly improve the quality of life for those affected by this condition.

If a woman is 55 years old or older and experiences postmenopausal bleeding (which occurs after 12 months of no menstruation), she should be referred for further evaluation within 2 weeks using the suspected cancer pathway to rule out endometrial cancer.

Endometrial cancer is a type of cancer that is commonly found in women who have gone through menopause, but it can also occur in around 25% of cases before menopause. The prognosis for this type of cancer is usually good due to early detection. There are several risk factors associated with endometrial cancer, including obesity, nulliparity, early menarche, late menopause, unopposed estrogen, diabetes mellitus, tamoxifen, polycystic ovarian syndrome, and hereditary non-polyposis colorectal carcinoma. Postmenopausal bleeding is the most common symptom of endometrial cancer, which is usually slight and intermittent initially before becoming more heavy. Pain is not common and typically signifies extensive disease, while vaginal discharge is unusual.

When investigating endometrial cancer, women who are 55 years or older and present with postmenopausal bleeding should be referred using the suspected cancer pathway. The first-line investigation is trans-vaginal ultrasound, which has a high negative predictive value for a normal endometrial thickness (< 4 mm). Hysteroscopy with endometrial biopsy is also commonly used for investigation. The management of localized disease involves total abdominal hysterectomy with bilateral salpingo-oophorectomy, while patients with high-risk disease may have postoperative radiotherapy. progesterone therapy is sometimes used in frail elderly women who are not considered suitable for surgery. It is important to note that the combined oral contraceptive pill and smoking are protective against endometrial cancer.

Investigating Infertility: Recommended Tests and Procedures

When a patient presents with infertility, there are several tests and procedures that can be performed to identify the underlying cause. In the case of a patient with known co-morbidities such as previous ectopic pregnancy, pelvic inflammatory disease, or endometriosis, laparoscopy and dye is the most appropriate next step of investigation. This procedure involves Exploratory laparoscopy, allowing direct visualisation of the pelvis, and injection of dye into the uterus to assess tubal patency.

Luteinising hormone (LH) and follicle-stimulating hormone (FSH) testing is typically performed when a patient has irregular menses, but may not be necessary for those with regular cycles and normal mid-luteal progesterone levels indicating ovulation. Basal body temperature charts are not recommended by NICE guidelines, as a mid-luteal phase progesterone blood test is a more accurate measure of ovulation.

Cervical smears may be indicated if the patient is due for screening, but do not form part of infertility investigations. Hysterosalpingography is recommended by NICE guidelines for women without co-morbidities, but is not appropriate for those with a history of endometriosis. Understanding the appropriate tests and procedures for investigating infertility can help healthcare providers identify the underlying cause and develop an effective treatment plan.

The Evra patch is the only contraceptive patch that is approved for use in the UK. The patch cycle lasts for four weeks, during which the patch is worn every day for the first three weeks and changed weekly. During the fourth week, the patch is not worn, and a withdrawal bleed occurs.

If a woman delays changing the patch at the end of week one or two, she should change it immediately. If the delay is less than 48 hours, no further precautions are necessary. However, if the delay is more than 48 hours, she should change the patch immediately and use a barrier method of contraception for the next seven days. If she has had unprotected sex during this extended patch-free interval or in the last five days, emergency contraception should be considered.

If the patch removal is delayed at the end of week three, the woman should remove the patch as soon as possible and apply a new patch on the usual cycle start day for the next cycle, even if withdrawal bleeding is occurring. No additional contraception is needed.

If patch application is delayed at the end of a patch-free week, additional barrier contraception should be used for seven days following any delay at the start of a new patch cycle. For more information, please refer to the NICE Clinical Knowledge Summary on combined hormonal methods of contraception.

Hormone Replacement Therapy (HRT) Options for Women with a History of DVT

Women with a history of deep vein thrombosis (DVT) need to be cautious when considering Hormone Replacement Therapy (HRT) options. Here are some options:

1. Transdermal Combined HRT Patches: This option is the best as it bypasses the enterohepatic circulation, reducing the effect on the hepatic clotting system.

2. Oral Continuous Combined HRT: This option is only suitable for postmenopausal women who have not had a period for over a year.

3. Oral Sequential Combined HRT: This option is suitable for perimenopausal women who are still having periods. However, oral preparations increase the risk of clots, compared to transdermal preparations.

4. Raloxifene: This is a selective oestrogen receptor modulator (SERM) that reduces osteoporosis in postmenopausal women. It has effects on lipids and bone but does not stimulate the endometrium or breast.

5. Tibolone: This synthetic steroid has oestrogenic, progestational, and androgenic properties. It is only suitable for postmenopausal women who had their last period more than a year ago.

In conclusion, women with a history of DVT should consult their healthcare provider before starting any HRT option. Transdermal combined HRT patches may be the safest option for these women.

The most appropriate method of HRT for the patient in this scenario is a transdermal oestrogen patch, as she has had a hysterectomy and oestrogen monotherapy is the regimen of choice. As the patient’s BMI is > 30 kg/m2, an oral oestrogen preparation is not recommended due to the increased risk of venous thromboembolism. HRT has benefits for the patient, including protection against osteoporosis, urogenital atrophy, and cardiovascular disorders. However, HRT also has risks, including an increased risk of venous thromboembolism and endometrial and breast cancer. Type 2 diabetes mellitus is not a contraindication to HRT, and there is no evidence that HRT affects glucose control. Combination HRT regimens are reserved for women with a uterus, and oral oestradiol once daily is not recommended for patients with a BMI > 30 kg/m2 due to the increased risk of venous thromboembolism. Women at high risk of developing venous thromboembolism or those with a strong family history or thrombophilia should be referred to haematology before starting HRT.

If a patient with endometriosis is not experiencing relief from their symptoms with a combination of non-steroidal anti-inflammatories and the combined oral contraceptive pill, they may be prescribed gonadotrophin-releasing hormone agonists (GnRH agonists) as a second-line medical management option. progesterone-only contraception may also be offered in this stage of treatment. GnRH agonists work by down-regulating GnRH receptors, which reduces the production of oestrogen and androgen. This reduction in hormones can alleviate the symptoms of endometriosis, as oestrogen thickens the uterine lining. The copper intrauterine device is not an appropriate treatment option, as it does not contain hormones and may actually worsen symptoms. NICE does not recommend the use of opioids in the management of endometriosis, as there is a high risk of adverse effects and addiction. Amitriptyline may be considered as a treatment option for chronic pain, but it is important to explore other medical and surgical options for endometriosis before prescribing it, as it comes with potential side effects and risks.

Understanding Endometriosis

Endometriosis is a common condition where endometrial tissue grows outside of the uterus. It affects around 10% of women of reproductive age and can cause chronic pelvic pain, painful periods, painful intercourse, and subfertility. Other symptoms may include urinary problems and painful bowel movements. Diagnosis is typically made through laparoscopy, and treatment options depend on the severity of symptoms.

First-line treatments for symptomatic relief include NSAIDs and/or paracetamol. If these do not help, hormonal treatments such as the combined oral contraceptive pill or progestogens may be tried. If symptoms persist or fertility is a priority, referral to secondary care may be necessary. Secondary treatments may include GnRH analogues or surgery. For women trying to conceive, laparoscopic excision or ablation of endometriosis plus adhesiolysis is recommended, as well as ovarian cystectomy for endometriomas.

It is important to note that there is poor correlation between laparoscopic findings and severity of symptoms, and that there is little role for investigation in primary care. If symptoms are significant, referral for a definitive diagnosis is recommended.

Surgical intervention is necessary for the management of ectopic pregnancy.

Ectopic pregnancy is a serious condition that requires prompt investigation and management. Women who are stable are typically investigated and managed in an early pregnancy assessment unit, while those who are unstable should be referred to the emergency department. The investigation of choice for ectopic pregnancy is a transvaginal ultrasound, which will confirm the presence of a positive pregnancy test.

There are three ways to manage ectopic pregnancies: expectant management, medical management, and surgical management. The choice of management will depend on various criteria, such as the size of the ectopic pregnancy, whether it is ruptured or not, and the patient’s symptoms and hCG levels. Expectant management involves closely monitoring the patient over 48 hours, while medical management involves giving the patient methotrexate and requires follow-up. Surgical management can involve salpingectomy or salpingostomy, depending on the patient’s risk factors for infertility.

Salpingectomy is the first-line treatment for women without other risk factors for infertility, while salpingostomy should be considered for women with contralateral tube damage. However, around 1 in 5 women who undergo a salpingostomy require further treatment, such as methotrexate and/or a salpingectomy. It is important to carefully consider the patient’s individual circumstances and make a decision that will provide the best possible outcome.

Understanding Premenstrual Syndrome (PMS)

Premenstrual syndrome (PMS) is a condition that affects women during the luteal phase of their menstrual cycle. It is characterized by emotional and physical symptoms that can range from mild to severe. PMS only occurs in women who have ovulatory menstrual cycles and does not occur before puberty, during pregnancy, or after menopause.

Emotional symptoms of PMS include anxiety, stress, fatigue, and mood swings. Physical symptoms may include bloating and breast pain. The severity of symptoms varies from woman to woman, and management options depend on the severity of symptoms.

Mild symptoms can be managed with lifestyle advice, such as getting enough sleep, exercising regularly, and avoiding smoking and alcohol. Specific advice includes eating regular, frequent, small, balanced meals that are rich in complex carbohydrates.

Moderate symptoms may benefit from a new-generation combined oral contraceptive pill (COCP), such as Yasmin® (drospirenone 3 mg and ethinylestradiol 0.030 mg). Severe symptoms may benefit from a selective serotonin reuptake inhibitor (SSRI), which can be taken continuously or just during the luteal phase of the menstrual cycle (for example, days 15-28, depending on the length of the cycle). Understanding PMS and its management options can help women better cope with this common condition.

If two consecutive samples are deemed inadequate during cervical cancer screening, the correct course of action is to refer the patient for colposcopy. Repeating the smear in 1 or 3 months is not appropriate as two inadequate samples have already been taken. Requesting hrHPV testing from the laboratory is also not useful if the sample is inadequate. Referring the patient to gynaecology is not necessary, and instead, a referral for colposcopy should be made.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

Surgical removal of the tumour is the primary treatment for ovarian cancers in stages 2-4, often accompanied by chemotherapy as well, according to NICE CG122.

Ovarian cancer is a common malignancy in women, ranking fifth in frequency. It is most commonly diagnosed in women over the age of 60 and has a poor prognosis due to late detection. The majority of ovarian cancers, around 90%, are of epithelial origin, with serous carcinomas accounting for 70-80% of cases. Interestingly, recent research suggests that many ovarian cancers may actually originate in the distal end of the fallopian tube. Risk factors for ovarian cancer include a family history of BRCA1 or BRCA2 gene mutations, early menarche, late menopause, and nulliparity.

Clinical features of ovarian cancer are often vague and can include abdominal distension and bloating, abdominal and pelvic pain, urinary symptoms such as urgency, early satiety, and diarrhea. The initial diagnostic test recommended by NICE is a CA125 blood test, although this can also be elevated in other conditions such as endometriosis and benign ovarian cysts. If the CA125 level is raised, an urgent ultrasound scan of the abdomen and pelvis should be ordered. However, a CA125 test should not be used for screening asymptomatic women. Diagnosis of ovarian cancer is difficult and usually requires a diagnostic laparotomy.

Management of ovarian cancer typically involves a combination of surgery and platinum-based chemotherapy. Unfortunately, 80% of women have advanced disease at the time of diagnosis, leading to a 5-year survival rate of only 46%. It was previously thought that infertility treatment increased the risk of ovarian cancer due to increased ovulation, but recent evidence suggests that this is not a significant factor. In fact, the combined oral contraceptive pill and multiple pregnancies have been shown to reduce the risk of ovarian cancer by reducing the number of ovulations.

This individual has reached the postmenopausal stage, indicated by the absence of menstruation for 12 consecutive months. However, despite being postmenopausal, she still requires contraception as she is below the age of 50. According to guidelines, women who use non-hormonal contraception can discontinue after one year of amenorrhea if they are over 50 years old, and after two years if they are under 50 years old. Given her history of breast cancer, a copper coil is the most suitable option as all other hormonal methods are classified as UKMEC Category 3, which may pose an unacceptable risk.

Women over 40 years old still need effective contraception until menopause. All methods of contraception are generally safe for this age group, except for the COCP and Depo-Provera which have some limitations. COCP use may help maintain bone mineral density and reduce menopausal symptoms, but a pill with less than 30 µg ethinylestradiol may be more suitable for women over 40. Depo-Provera use is associated with a small loss in bone mineral density and may cause a delay in the return of fertility for up to 1 year for women over 40. The FSRH provides guidance on how to stop different methods of contraception based on age and amenorrhea status. HRT cannot be relied upon for contraception, and a separate method is needed. The POP may be used with HRT as long as the HRT has a progesterone component, while the IUS is licensed to provide the progesterone component of HRT.

Ectopic Pregnancy: Sites and Symptoms

Ectopic pregnancy is a condition where the fertilized egg implants outside the uterine cavity. The most common site for ectopic implantation is the Fallopian tube, particularly the ampullary region, accounting for 97% of cases. Symptoms include 4-8 weeks of amenorrhea, abdominal pain, vaginal bleeding, and signs of shock associated with rupture. Shoulder tip pain may also occur due to irritation of the phrenic nerve. Diagnosis is made through measurement of β-human chorionic gonadotrophin and ultrasound scan of the abdomen, with laparoscopic investigation as the definitive method. Treatment involves removal of the pregnancy and often the affected tube via laparoscopy or laparotomy.

Other sites for ectopic pregnancy include the peritoneum or abdominal cavity, which accounts for 1.4% of cases and may proceed to term. Cervical pregnancy is rare, accounting for less than 1% of cases. Ovarian pregnancy occurs in 1 in 7000 pregnancies and accounts for 0.5-3% of all ectopic pregnancies. The broad ligament is an uncommon site for ectopic pregnancies due to its poor vascularity.

If a cervical smear is inadequate, it is recommended to repeat the test within 3 months. This is the correct course of action for the patient in question, as her routine smear was deemed inadequate. Referral for colposcopy is not necessary at this stage, as it is only indicated if there are two consecutive inadequate smears that are 3 months apart. Waiting for 3 years to repeat the smear would not be appropriate, as this is the interval for routine recall for a patient of her age. Similarly, waiting for 6 or 12 months to repeat the smear would not be appropriate, as these timeframes are only indicated for specific circumstances such as testing for cure following treatment or if the most recent smear was hrHPV positive without cytological abnormalities.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

Understanding Premenstrual Syndrome (PMS)

Premenstrual syndrome (PMS) is a condition that affects women during the luteal phase of their menstrual cycle. It is characterized by emotional and physical symptoms that can range from mild to severe. PMS only occurs in women who have ovulatory menstrual cycles and does not occur before puberty, during pregnancy, or after menopause.

Emotional symptoms of PMS include anxiety, stress, fatigue, and mood swings. Physical symptoms may include bloating and breast pain. The severity of symptoms varies from woman to woman, and management options depend on the severity of symptoms.

Mild symptoms can be managed with lifestyle advice, such as getting enough sleep, exercising regularly, and avoiding smoking and alcohol. Specific advice includes eating regular, frequent, small, balanced meals that are rich in complex carbohydrates.

Moderate symptoms may benefit from a new-generation combined oral contraceptive pill (COCP), such as Yasmin® (drospirenone 3 mg and ethinylestradiol 0.030 mg). Severe symptoms may benefit from a selective serotonin reuptake inhibitor (SSRI), which can be taken continuously or just during the luteal phase of the menstrual cycle (for example, days 15-28, depending on the length of the cycle). Understanding PMS and its management options can help women better cope with this common condition.

Distinguishing between common vaginal infections: Trichomoniasis, Bacterial Vaginosis, gonorrhoeae, Chlamydia, and Mycoplasma Genitalium

When a woman presents with an elevated vaginal pH, a fish-smelling, yellow vaginal discharge, and ovoid trichomonads, the diagnosis of trichomoniasis (Trichomonas vaginalis) is strongly supported. A wet saline mount or anaerobic culture can confirm the diagnosis, with culture being particularly useful in men. Treatment involves oral metronidazole for seven days or a single 2g dose, and sexual partners should also be treated to prevent re-infection.

Bacterial vaginosis is a differential diagnosis to consider, as it also presents with a fish-smelling discharge and a pH > 4.5. However, the presence of ovoid mobile parasites on wet saline mount suggests trichomoniasis as the more likely diagnosis. Bacterial vaginosis would show clue cells on wet saline mount.

gonorrhoeae and Chlamydia are sexually transmitted infections that are more likely to be seen in patients with a history of unprotected sex. However, fish-smelling discharge is not characteristic of either infection. A specimen culture of gonorrhoeae would show Gram-negative diplococci, while chlamydia would not show ovoid mobile parasites on wet saline mount.

Mycoplasma genitalium is another potential sexually transmitted infection that can cause urethritis, discharge, cervicitis, or endometritis in women. However, the wet saline mount results suggest that this is not the diagnosis, and fish-smelling discharge is not characteristic of this infection.

In summary, a combination of clinical presentation, wet saline mount, and culture can help distinguish between common vaginal infections such as trichomoniasis, bacterial vaginosis, gonorrhoeae, chlamydia, and mycoplasma genitalium.

Fitz-Hugh-Curtis syndrome is characterized by hepatic adhesions, which are not present in any of the other options. Therefore, the diagnosis is based on the presence of lesions rather than just the symptoms described. This syndrome is a complication of PID that causes inflammation of the liver capsule, known as Glisson’s Capsule.

Gynaecological Causes of Abdominal Pain in Women

Abdominal pain is a common complaint among women, and it can be caused by various gynaecological disorders. To diagnose these disorders, a bimanual vaginal examination, urine pregnancy test, and abdominal and pelvic ultrasound scanning should be performed in addition to routine diagnostic workup. If diagnostic doubt persists, a laparoscopy can be used to assess suspected tubulo-ovarian pathology.

There are several differential diagnoses of abdominal pain in females, including mittelschmerz, endometriosis, ovarian torsion, ectopic gestation, and pelvic inflammatory disease. Mittelschmerz is characterized by mid-cycle pain that usually settles over 24-48 hours. Endometriosis is a complex disease that may result in pelvic adhesional formation with episodes of intermittent small bowel obstruction. Ovarian torsion is usually sudden onset of deep-seated colicky abdominal pain associated with vomiting and distress. Ectopic gestation presents as an emergency with evidence of rupture or impending rupture. Pelvic inflammatory disease is characterized by bilateral lower abdominal pain associated with vaginal discharge and dysuria.

Each of these disorders requires specific investigations and treatments. For example, endometriosis is usually managed medically, but complex disease may require surgery and some patients may even require formal colonic and rectal resections if these areas are involved. Ovarian torsion is usually diagnosed and treated with laparoscopy. Ectopic gestation requires a salpingectomy if the patient is haemodynamically unstable. Pelvic inflammatory disease is usually managed medically with antibiotics.

The contraceptive implant primarily works by inhibiting ovulation through the slow release of progesterone hormone. While it also increases cervical mucous thickness, this is not its main mode of action. The progesterone-only pill also increases cervical mucous thickness, while the intrauterine copper device decreases sperm viability. The intrauterine system prevents implantation of the ovum by exerting local progesterone onto the uterine lining.

Understanding the Mode of Action of Contraceptives

Contraceptives are used to prevent unwanted pregnancies. They work by different mechanisms depending on the type of contraceptive used. The Faculty for Sexual and Reproductive Health (FSRH) has provided a table that outlines the mode of action of standard contraceptives and emergency contraception.

Standard contraceptives include the combined oral contraceptive pill, progesterone-only pill, injectable contraceptive, implantable contraceptive, and intrauterine contraceptive device/system. The combined oral contraceptive pill and injectable/implantable contraceptives primarily work by inhibiting ovulation, while the progesterone-only pill and some injectable/implantable contraceptives thicken cervical mucous to prevent sperm from reaching the egg. The intrauterine contraceptive device/system decreases sperm motility and survival and prevents endometrial proliferation.

Emergency contraception, which is used after unprotected sex or contraceptive failure, also works by different mechanisms. Levonorgestrel and ulipristal inhibit ovulation, while the intrauterine contraceptive device is toxic to sperm and ovum and inhibits implantation.

Understanding the mode of action of contraceptives is important in choosing the most appropriate method for an individual’s needs and preferences. It is also important to note that no contraceptive method is 100% effective, and the use of condoms can provide additional protection against sexually transmitted infections.

To manage premenstrual syndrome, it is recommended to make specific lifestyle changes such as regular exercise and consuming small, balanced meals rich in complex carbohydrates every 2-3 hours. These changes are advised by the Royal College of Obstetrics and Gynaecology as a first-line management approach. It is also suggested to quit smoking, reduce alcohol intake, maintain regular sleep patterns, and manage stress levels. Contrary to popular belief, reducing dietary fats and carbohydrates is not recommended. Additionally, prescribing diazepam is not a routine management approach and is only used in select cases where anxiety is a significant symptom. Selective serotonin reuptake inhibitors like sertraline can be used for severe premenstrual syndrome, but lifestyle changes are usually sufficient for mild symptoms that do not interfere with daily life.

Understanding Premenstrual Syndrome (PMS)

Premenstrual syndrome (PMS) is a condition that affects women during the luteal phase of their menstrual cycle. It is characterized by emotional and physical symptoms that can range from mild to severe. PMS only occurs in women who have ovulatory menstrual cycles and does not occur before puberty, during pregnancy, or after menopause.

Emotional symptoms of PMS include anxiety, stress, fatigue, and mood swings. Physical symptoms may include bloating and breast pain. The severity of symptoms varies from woman to woman, and management options depend on the severity of symptoms.

Mild symptoms can be managed with lifestyle advice, such as getting enough sleep, exercising regularly, and avoiding smoking and alcohol. Specific advice includes eating regular, frequent, small, balanced meals that are rich in complex carbohydrates.

Moderate symptoms may benefit from a new-generation combined oral contraceptive pill (COCP), such as Yasmin® (drospirenone 3 mg and ethinylestradiol 0.030 mg). Severe symptoms may benefit from a selective serotonin reuptake inhibitor (SSRI), which can be taken continuously or just during the luteal phase of the menstrual cycle (for example, days 15-28, depending on the length of the cycle). Understanding PMS and its management options can help women better cope with this common condition.

Methods for Checking Ovulation

There are several methods for checking ovulation, but not all of them are definitive. The easiest way to check for ovulation is through a day-21 progesterone level test, which measures the progesterone released by the corpus luteum after ovulation. However, an increase in basal body temperature is not a definitive indicator of ovulation.

Luteinising hormone (LH) and follicle stimulating hormone (FSH) are released from the pituitary gland and cause the development of the follicle ready for ovulation. However, if the day-21 progesterone level is normal, then FSH and LH will also be normal. An endometrial biopsy may confirm the absence of any uterine abnormality, but it does not ensure ovulation has taken place.

The cervical fern test is an assessment of cervical mucous, which is dependent on hormone levels. However, there is diagnostic uncertainty with this method, and measuring hormone levels directly is a more reliable indicator of ovulation. Overall, a combination of these methods may be used to confirm ovulation.

The patient is likely taking the progesterone-only contraceptive pill due to her history of migraine with aura and daily use of the contraceptive pill. According to the BNF, antibacterials that do not induce liver enzymes do not affect the effectiveness of oral progesterone-only preparations. As ciprofloxacin is a cytochrome P450 inhibitor and not an inducer, the patient’s contraception is not affected, and she does not require additional barrier contraception. However, if the patient were taking rifampicin, an alternative for meningococcal contact prophylaxis, she would need to use barrier contraception during and for four weeks after stopping treatment. Rifampicin is a potent enzyme inducer, which can decrease the plasma concentration and efficacy of contraceptive pills.

Counselling for Women Considering the progesterone-Only Pill

Women who are considering taking the progesterone-only pill (POP) should receive counselling on various aspects of the medication. One of the most common potential adverse effects is irregular vaginal bleeding. When starting the POP, immediate protection is provided if it is commenced up to and including day 5 of the cycle. If it is started later, additional contraceptive methods such as condoms should be used for the first 2 days. If switching from a combined oral contraceptive (COC), immediate protection is provided if the POP is continued directly from the end of a pill packet.

It is important to take the POP at the same time every day, without a pill-free break, unlike the COC. If a pill is missed by less than 3 hours, it should be taken as normal. If it is missed by more than 3 hours, the missed pill should be taken as soon as possible, and extra precautions such as condoms should be used until pill taking has been re-established for 48 hours. Diarrhoea and vomiting do not affect the POP, but assuming pills have been missed and following the above guidelines is recommended. Antibiotics have no effect on the POP, unless they alter the P450 enzyme system, such as rifampicin. Liver enzyme inducers may reduce the effectiveness of the POP.

In addition to these specific guidelines, women should also have a discussion on sexually transmitted infections (STIs) when considering the POP. It is important for women to receive comprehensive counselling on the POP to ensure they are aware of its potential effects and how to use it effectively.

When a woman experiences postmenopausal bleeding (PMB), the primary concern is the possibility of endometrial cancer. This is because endometrial adenocarcinoma is strongly linked to PMB and early detection is crucial for better prognosis. The patient in this scenario has two risk factors for endometrial adenocarcinoma – obesity and hypertension. Other risk factors include high levels of oestrogen, late menopause, polycystic ovarian syndrome, diabetes mellitus, and tamoxifen use.

Endometrial cancer is a type of cancer that is commonly found in women who have gone through menopause, but it can also occur in around 25% of cases before menopause. The prognosis for this type of cancer is usually good due to early detection. There are several risk factors associated with endometrial cancer, including obesity, nulliparity, early menarche, late menopause, unopposed estrogen, diabetes mellitus, tamoxifen, polycystic ovarian syndrome, and hereditary non-polyposis colorectal carcinoma. Postmenopausal bleeding is the most common symptom of endometrial cancer, which is usually slight and intermittent initially before becoming more heavy. Pain is not common and typically signifies extensive disease, while vaginal discharge is unusual.

When investigating endometrial cancer, women who are 55 years or older and present with postmenopausal bleeding should be referred using the suspected cancer pathway. The first-line investigation is trans-vaginal ultrasound, which has a high negative predictive value for a normal endometrial thickness (< 4 mm). Hysteroscopy with endometrial biopsy is also commonly used for investigation. The management of localized disease involves total abdominal hysterectomy with bilateral salpingo-oophorectomy, while patients with high-risk disease may have postoperative radiotherapy. progesterone therapy is sometimes used in frail elderly women who are not considered suitable for surgery. It is important to note that the combined oral contraceptive pill and smoking are protective against endometrial cancer.

Patients who have taken ulipristal acetate should wait for 5 days before resuming regular hormonal contraception. This is because hormonal contraception may be less effective when taken with ulipristal acetate, which could compromise its ability to prevent ovulation. However, there is an exception to this rule. If a patient is already taking the combined oral contraceptive pill (COCP) and has missed pills later than the first week of taking them, they can resume the COCP immediately after taking ulipristal acetate. Otherwise, patients should wait for 5 days before restarting hormonal contraception and use barrier methods during this period. It is not necessary to take a pregnancy test after taking ulipristal acetate unless the patient’s next period is more than 7 days late or lighter than usual. It is not contraindicated to use hormonal contraception with ulipristal acetate, but it is recommended to wait for 5 days before resuming it.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, while ulipristal primarily inhibits ovulation. Levonorgestrel should be taken as soon as possible after unprotected sexual intercourse, within 72 hours, and is 84% effective when used within this time frame. The dose should be doubled for those with a BMI over 26 or weight over 70kg. Ulipristal should be taken within 120 hours of intercourse and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which can be inserted within 5 days of unprotected intercourse or up to 5 days after the likely ovulation date. It may inhibit fertilization or implantation and is 99% effective regardless of where it is used in the cycle. Prophylactic antibiotics may be given if the patient is at high risk of sexually transmitted infection.

Differentiating Gynecologic Cancers: Understanding the Symptoms and Metastasis Patterns

When a postmenopausal woman presents with vaginal bleeding, pelvic mass, and pelvic lymphadenopathy, it is important to consider the different types of gynecologic cancers that may be causing these symptoms.

Cervical squamous cell carcinoma is the most likely diagnosis in this case, as it typically metastasizes to the pelvic lymph nodes along the iliac arteries. On the other hand, endometrial carcinoma first metastasizes to the para-aortic lymph nodes, while ovarian malignancies typically spread to the para-aortic lymph nodes and are not associated with vaginal bleeding.

Uterine leiomyosarcoma, which is the most common type of sarcoma in the female pelvis, often extends beyond the uterine serosa and may metastasize to distant organs through blood vessels. However, vaginal bleeding and pelvic lymphadenopathy are not typical features of this cancer.

Cervical adenocarcinomas, which are rare and account for about 25% of cervical cancers, are associated with human papillomavirus and prolonged exposure to exogenous estrogens, but not with smoking. Their presentation and management are similar to those of squamous cancer.

Understanding the symptoms and metastasis patterns of different gynecologic cancers is crucial in making an accurate diagnosis and providing appropriate treatment.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, while ulipristal primarily inhibits ovulation. Levonorgestrel should be taken as soon as possible after unprotected sexual intercourse, within 72 hours, and is 84% effective when used within this time frame. The dose should be doubled for those with a BMI over 26 or weight over 70kg. Ulipristal should be taken within 120 hours of intercourse and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which can be inserted within 5 days of unprotected intercourse or up to 5 days after the likely ovulation date. It may inhibit fertilization or implantation and is 99% effective regardless of where it is used in the cycle. Prophylactic antibiotics may be given if the patient is at high risk of sexually transmitted infection.